Top Page
AuMake Ltd.
(Sydney:AUK)
AuMake Ltd. (AUK) vs. iShares MSCI Australia ETF (EWA)
AuMake Ltd. Business Overview & Revenue Model
AuMake Ltd. Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 39.89M | 39.77M | 25.87M | 2.67M | 6.01M | 12.44M |
| Gross Profit | 1.09M | 968.93K | 843.62K | 60.17K | 551.40K | 1.78M |
| EBITDA | -3.33M | -3.39M | -5.85M | -2.11M | -4.78M | -19.71M |
| Net Income | -3.42M | -3.48M | -6.28M | -3.03M | -6.18M | -20.12M |
Balance Sheet | ||||||
| Total Assets | 8.30M | 8.30M | 4.37M | 6.37M | 10.08M | 17.34M |
| Cash, Cash Equivalents and Short-Term Investments | 1.72M | 1.72M | 2.03M | 1.55M | 3.04M | 4.26M |
| Total Debt | 1.16M | 1.16M | 2.19M | 0.00 | 520.24K | 3.06M |
| Total Liabilities | 5.64M | 5.64M | 3.80M | 1.26M | 5.98M | 11.98M |
| Stockholders Equity | 2.55M | 2.55M | 524.74K | 5.11M | 4.18M | 5.39M |
Cash Flow | ||||||
| Free Cash Flow | -4.26M | -4.26M | -2.84M | -3.46M | -5.35M | -10.48M |
| Operating Cash Flow | -4.26M | -4.26M | -2.66M | -3.46M | -4.64M | -7.99M |
| Investing Cash Flow | -38.83K | -38.83K | -318.20K | -192.52K | 589.87K | -2.59M |
| Financing Cash Flow | 3.93M | 3.93M | 3.58M | 2.00M | 2.59M | 6.59M |
AuMake Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | AU$87.20M | 3.99 | 34.61% | 17.89% | 6.15% | -32.02% | |
71 Outperform | AU$62.09M | 4.90 | 24.28% | 20.30% | 2.76% | 1.93% | |
61 Neutral | $18.38B | 12.79 | -2.54% | 3.03% | 1.52% | -15.83% | |
37 Underperform | AU$11.54M | ― | -226.65% | ― | 53.75% | 57.58% |
AuMake Ltd. Corporate Events
AuMake Limited has applied to the ASX for quotation of 19.5 million new fully paid ordinary shares under its AUK ticker, in line with the exchange’s listing rules. The additional securities, issued on 22 December 2025, expand the company’s quoted share capital and may affect ownership structures and liquidity for existing and prospective shareholders, though the announcement provides no further detail on the purpose or use of proceeds from this issuance.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has applied to the ASX for quotation of 750 million new ordinary fully paid shares under its issuer code AUK, with an issue date of 22 December 2025. The substantial increase in quoted securities, issued as part of a previously announced transaction, will significantly expand the company’s share base, potentially affecting existing shareholder dilution, trading liquidity and the company’s capacity to raise or deploy capital in line with its strategic objectives.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
Aumake Limited has secured a pharmaceutical wholesale license in Hong Kong, enabling the launch of up to five online OTC stores to serve China’s rapidly growing over-the-counter (OTC) medicine market. With the potential to acquire additional licenses for further expansion, this move positions Aumake to capitalize on structural changes in China’s healthcare system, growing demand for safe, high-quality OTC products, and the rise of e-commerce. Supported by sourcing agreements, logistics capabilities, and proven e-commerce expertise, Aumake is set to establish itself as a key player in the high-growth OTC sector while creating significant growth opportunities for stakeholders.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced the appointment of Zoran Grujic as a director, effective December 17, 2025. The initial director’s interest notice reveals that Grujic currently holds no relevant interests in securities or contracts with the company, indicating a fresh start in his role. This appointment may impact the company’s strategic direction and governance, potentially influencing stakeholder confidence and market perception.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced the appointment of Mr. Zoran Grujic as a Non-Executive Director, effective December 17, 2025. Mr. Grujic brings over 20 years of experience in leadership roles across various industries, including financial services, FMCG, and SaaS technology. His extensive background in financial management and governance is expected to enhance AuMake’s compliance, financial control, and transparency, strengthening the company’s board with his expertise.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced a change of address for its registered office and principal place of business to Suite 1507, World Tower, 87-89 Liverpool St, Sydney NSW 2000. This change, authorized by the company’s board, reflects a strategic move that may impact its operational efficiency and stakeholder engagement.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced a proposed issue of 750 million unquoted options and ordinary fully paid securities, with an exercise price of $0.004 each, set to expire two years from the date of issue. This strategic move is aimed at raising capital and potentially enhancing the company’s market position, reflecting its ongoing efforts to strengthen its financial foundation and expand its operational capabilities.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has successfully raised $1.5 million through a placement to institutional, professional, and sophisticated investors. This capital will be used to bolster inventory, working capital, and cover placement costs, supporting the company’s strategic objectives for 2026, including expanding its Australian brand portfolio and enhancing marketing efforts in China. The capital raising reflects investor confidence in the company’s governance and management’s focus on execution.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has requested a trading halt on its securities as it plans a significant capital raising initiative. This strategic move is expected to impact the company’s financial operations and market positioning, with the halt lasting until the announcement is made or until normal trading resumes on December 11, 2025.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Ltd. has released an investor update highlighting its strategic focus on the Asian market, aiming to enhance its market positioning and operational impact. The company acknowledges various risks such as the impact of COVID-19, competition, and reliance on key personnel, which could affect its financial performance and stakeholder interests.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced the issuance of fully paid ordinary shares without disclosure under Part 6D.2 of the Corporations Act, as per the notice under section 708A(5)(e). The company confirms compliance with relevant provisions of the Corporations Act and states that there is no excluded information that would typically be expected in a disclosure document. This move signifies AuMake’s strategic approach to managing its share capital and maintaining transparency with its investors.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited, listed on the Australian Securities Exchange under the code AUK, has announced the quotation of 55 million ordinary fully paid securities as of December 5, 2025. This move is part of the company’s strategic financial activities, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Ltd. announced the resignation of Director Jiahua (Joshua) Zhou, effective November 28, 2025. Zhou’s departure involves the transfer of his interests in 117,560,672 ordinary shares held by Zhous Australia Holding Pty Ltd. This change in leadership may impact the company’s strategic direction and stakeholder interests.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced the cessation of Zhao Zhang as a director, effective from November 28, 2025. Zhao Zhang, who held significant interests in the company through New Continent Australia Pty Ltd, had 100 million fully paid ordinary shares and 100 million unquoted options. This change in directorship may impact the company’s governance and strategic direction, potentially affecting stakeholders and market perceptions.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced the appointment of Carl Hagon as a director, effective November 27, 2025. The initial director’s interest notice reveals that Hagon currently holds no relevant interests in securities, either as a registered holder or through other entities, nor does he have any interests in contracts related to the company. This appointment is a procedural update and does not indicate any immediate changes to the company’s operations or market strategy.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
Aumake Limited announced the results of its annual general meeting, where all resolutions were passed by poll, although Resolution 2 and Resolution 3 were withdrawn. This outcome signifies a smooth operational process for the company, potentially reinforcing its strategic direction and stability in the market.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
Aumake Limited has announced changes to its Board of Directors to enhance governance and operational focus. Executive Directors Joshua Zhou and Tracy Zhou have resigned from the Board to concentrate on their respective business units, while Carl Hagon, an experienced attorney, has been appointed as a Non-Executive Director. These changes aim to separate board oversight from executive management, allowing for improved governance and operational efficiency, which is expected to lead to better commercial outcomes and strategic alignment.
The most recent analyst rating on (AU:AUK) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AuMake Ltd. stock, see the AU:AUK Stock Forecast page.
AuMake Limited has announced its 2025 Annual General Meeting (AGM) scheduled for November 28, 2025, at its Artarmon location. Shareholders are encouraged to participate in the meeting and vote on resolutions, either in person, by proxy, or online. The company emphasizes the use of electronic communications to keep shareholders informed efficiently, promoting environmental sustainability and cost reduction.
Aumake Limited has entered into a non-binding Cooperation Framework Agreement with Sinomach Hainan Development Co., Ltd., a subsidiary of China National Machinery Industry Corporation. This partnership marks Sinomach’s first commercial engagement in Australia and aims to develop a large-scale Premium Hay Supply Chain Project. The project will initially cover 3,000 hectares, with plans to expand to 20,000 hectares, targeting an annual production capacity of 300,000 tonnes. Aumake will manage the Australian operations, while Sinomach will provide technology, infrastructure, and capital support. This collaboration aligns with China’s broader strategy to strengthen international agricultural supply chains and offers Aumake access to Sinomach’s extensive resources and market demand.
Aumake Limited has launched Bio-Basic Ergothioneine, marking the first brand under its new capital-light incubation model. This strategy aims to develop high-margin health and wellness brands with minimal capital investment, allowing Aumake to retain acquisition rights for successful brands. The launch, supported by a partnership with Mijing Media, combines online and offline distribution channels, enhancing Aumake’s market positioning in China’s premium health market. The initiative demonstrates the viability of Aumake’s model and sets the stage for future brand developments.
AuMake Limited announced a late lodgement of Appendix 3Z related to Ms. Hai Yun Chen due to an administrative oversight. The company assured stakeholders that this is an isolated incident and affirmed their commitment to compliance with ASX Listing Rules, indicating no significant impact on their operations or industry positioning.